Oxidative stress and glutathione in TGF-β-mediated fibrogenesis

Free Radical Biology and Medicine

Volumn 48, Issue 1, 2010, Pages 1-15

  Liu, R M ^a   Gaston Pravia, K A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Fibrosis; Free radicals; Glutathione; Oxidative stress; TGF

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BROMHEXINE; CATALASE; CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY; COPPER ZINC SUPEROXIDE DISMUTASE; DEFEROXAMINE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; GLUTAREDOXIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; IMMUNOSUPPRESSIVE AGENT; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; MANGANESE SUPEROXIDE DISMUTASE; PLACEBO; PREDNISONE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNINDEXED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIOXIDANT ACTIVITY; APOPTOSIS; ASTHMA; CELL ACTIVATION; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG TARGETING; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSING ALVEOLITIS; FIBROSIS; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HEART MUSCLE FIBROSIS; HEPATITIS B; HEPATITIS C; HUMAN; KIDNEY FIBROSIS; LIVER CIRRHOSIS; LIVER FIBROSIS; LUNG FIBROSIS; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIOXIDANTS; FIBROSIS; GLUTATHIONE; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TRANSFORMING GROWTH FACTOR BETA;

EID: 74149085153     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.09.026     Document Type: Review

References (339)

1. Dekhuijzen P.N., Aben K.K., Dekker I., Aarts L.P., Wielders P.L., van Herwaarden C.L., and Bast A. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 154 (1996) 813-816
2. Rahman I., Morrison D., Donaldson K., and MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am. J. Respir. Crit. Care Med. 154 (1996) 1055-1060
3. Pratico D., Basili S., Vieri M., Cordova C., Violi F., and Fitzgerald G.A. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am. J. Respir. Crit. Care Med. 158 (1998) 1709-1714
4. Barreiro E., de la Puente B., Minguella J., Corominas J.M., Serrano S., Hussain S.N.A., and Gea J. Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 171 (2005) 1116-1124
5. Juul K., Tybjaerg-Hansen A., Marklund S., Lange P., and Nordestgaard B.G. Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 173 (2006) 858-864
6. Kuleci S., Hanta I., Kocabas A., and Canacankatan N. The effect of different treatment modalities on oxidative stress in COPD. Adv. Ther. 25 (2008) 710-717
7. Louhelainen N., Myllarniemi M., Rahman I., and Kinnula V.L. Airway biomarkers of the oxidant burden in asthma and chronic obstructive pulmonary disease: current and future perspectives. Int. J. Chronic Obstruct. Pulm. Dis. 3 (2008) 585-603
8. Maier K., Leuschel L., and Costabel U. Increased levels of oxidized methionine residues in bronchoalveolar lavage fluid proteins from patients with idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 143 (1991) 271-274
9. Rottoli P.B.M., Cianti R., Bargagli E., Vagaggini C., Nikiforakis N., Pallini V., and Bini L. Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 5 (2005) 2612-2618
10. Psathakis K., Mermigkis D., Papatheodorou G., Loukides S., Panagou P., Polychronopoulos V., Siafakas N.M., and Bouros D. Exhaled markers of oxidative stress in idiopathic pulmonary fibrosis. Eur. J. Clin. Invest. 36 (2006) 362-367
11. Starosta V., Rietschel E., Paul K., Baumann U., and Griese M. Oxidative changes of bronchoalveolar proteins in cystic fibrosis. Chest 129 (2006) 431-437
12. Rosias P.P.R., Hartog G.J.M.D., Robroeks C.M.H.H.T., Bast A., Donckerwolcke R.A.M.G., Heynens J.W.C.M., Suykerbuyk J., Hendriks H.J.E., Jöbsis Q., and Dompeling E. Free radicals in exhaled breath condensate in cystic fibrosis and healthy subjects. Free Radic. Res. 40 (2006) 901-909
13. Reid D.W., Misso N., Aggarwal S., Thompson P.J., and Walters E.H. Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis. Respirology 12 (2007) 63-69
14. Imai Y., Kuba K., Neely G.G., Yaghubian-Malhami R., Perkmann T., van Loo G., Ermolaeva M., Veldhuizen R., Leung Y.H.C., Wang H., Liu H., Sun Y., Pasparakis M., Kopf M., Mech C., Bavari S., Peiris J.S.M., Slutsky A.S., Akira S., Hultqvist M., Holmdahl R., Nicholls J., Jiang C., Binder C.J., and Penninger J.M. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133 (2008) 235-249
15. Pilger A., Germadnik D., Schaffer A., Theiler A., Pils P., Sluka F., Winker N., and Rudiger H.W. 8-Hydroxydeoxyguanosine in leukocyte DNA and urine of quartz-exposed workers and patients with silicosis. Int. Arch. Occup. Environ. Health 73 (2000) 305-310
16. Kim J. Urinary 8-hydroxy-2′-deoxyguanosine as a biomarker of oxidative DNA damage in workers exposed to fine particulates. Environ. Health Perspect. 112 (2004) 666
17. Pelclova D., Fenclova Z., Kacer P., Kuzma M., Navratil T., and Lebedova J. Increased 8-isoprostane, a marker of oxidative stress in exhaled breath condensate in subjects with asbestos exposure. Ind. Health 46 (2008) 484-489
18. Srivastava K.D., Rom W.N., Jagirdar J., Yie T.A., Gordon T., and Tchou-Wong K.M. Crucial role of interleukin-1beta and nitric oxide synthase in silica-induced inflammation and apoptosis in mice. Am. J. Respir. Crit. Care Med. 165 (2002) 527-533
19. Porter D.W., Millecchia L.L., Willard P., Robinson V.A., Ramsey D., McLaurin J., Khan A., Brumbaugh K., Beighley C.M., Teass A., and Castranova V. Nitric oxide and reactive oxygen species production causes progressive damage in rats after cessation of silica inhalation. Toxicol. Sci. 90 (2006) 188-197
20. Sato T., Takeno M., Honma K., Yamauchi H., Saito Y., Sasaki T., Morikubo H., Nagashima Y., Takagi S., Yamanaka K., Kaneko T., and Ishigatsubo Y. Heme oxygenase-1, a potential biomarker of chronic silicosis, attenuates silica-induced lung injury. Am. J. Respir. Crit. Care Med. 174 (2006) 906-914
21. Manoury B., Nenan S., Leclerc O., Guenon I., Boichot E., Planquois J.M., Bertrand C.P., and Lagente V. The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis. Respir. Res. 6 (2005) 11
22. Yildirim Z., Kotuk M., Iraz M., Kuku I., Ulu R., Armutcu F., and Ozen S. Attenuation of bleomycin-induced lung fibrosis by oral sulfhydryl containing antioxidants in rats: erdosteine and N-acetylcysteine. Pulm. Pharmacol. Ther. 18 (2005) 367-373
23. Liu R., Ahmed K.M., Nantajit D., Rosenthal F.S., Hai C.X., and Li J.J. Therapeutic effects of alpha-lipoic acid on bleomycin-induced pulmonary fibrosis in rats. Int. J. Mol. Med. 19 (2007) 865-873
24. Iyer S.S., Ramirez A.M., Ritzenthaler J.D., Torres-Gonzalez E., Roser-Page S., Mora A.L., Brigham K.L., Jones D.P., Roman J., and Rojas M. Oxidation of extracellular cysteine/cystine redox state in bleomycin-induced lung fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 296 (2009) L37-45
25. Perlemuter G., Letteron P., Carnot F., Zavala F., Pessayre D., Nalpas B., and Brechot C. Alcohol and hepatitis C virus core protein additively increase lipid peroxidation and synergistically trigger hepatic cytokine expression in a transgenic mouse model. J. Hepatol. 39 (2003) 1020-1027
26. Purohit V., and Brenner D.A. Mechanisms of alcohol-induced hepatic fibrosis: a summary of the Ron Thurman Symposium. Hepatology 43 (2006) 872-878
27. De Minicis S.D.A.B. Oxidative stress in alcoholic liver disease: role of NADPH oxidase complex. J. Gastroenterol. Hepatol. 23 (2008) S98-S103
28. Dionisio N., Garcia-Mediavilla M.V., Sanchez-Campos S., Majano P.L., Benedicto I., Rosado J.A., Salido G.M., and Gonzalez-Gallego J. Hepatitis C virus NS5A and core proteins induce oxidative stress-mediated calcium signalling alterations in hepatocytes. J. Hepatol. 50 (2009) 872-882
29. Yadav D., Hertan H.I., Schweitzer P., Norkus E.P., and Pitchumoni C.S. Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am. J. Gastroenterol. 97 (2002) 2634-2639
30. Bedossa P., and Paradis V. Approaches for treatment of liver fibrosis in chronic hepatitis C. Clin. Liver Dis. 7 (2003) 195-210
31. Seki S., Kitada T., and Sakaguchi H. Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatol. Res. 33 (2005) 132-134
32. Fujita N., Horiike S., Sugimoto R., Tanaka H., Iwasa M., Kobayashi Y., Hasegawa K., Ma N., Kawanishi S., Adachi Y., and Kaito M. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic. Biol. Med. 42 (2007) 353-362
33. Mantena S.K., King A.L., Andringa K.K., Eccleston H.B., and Bailey S.M. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic. Biol. Med. 44 (2008) 1259-1272
34. Urtasun R., de la Rosa L.C., and Nieto N. Oxidative and nitrosative stress and fibrogenic response. Clinics Liver Dis. Hepatic Fibr. 12 (2008) 769-790
35. Das K.S., Balakrishnan V., Mukherjee S., and Vasudevan D.M. Evaluation of blood oxidative stress-related parameters in alcoholic liver disease and non-alcoholic fatty liver disease. Scand. J. Clin. Lab. Invest. 68 (2008) 323-334
36. Pawlak K., Zolbach K., Borawski J., Mysliwiec M., Kovalchuk O., Chyczewski L., and Pawlak D. Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients. Thromb. Res. 123 (2008) 166-170
37. Macdonald G.A., Bridle K.R., Ward P.J., Walker N.I., Houglum K., George D.K., Smith J.L., Powell L.W., Crawford D.H., and Ramm G.A. Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3. J. Gastroenterol. Hepatol. 16 (2001) 599-606
38. Ha H., and Lee H.B. Reactive oxygen species and matrix remodeling in diabetic kidney. J. Am. Soc. Nephrol. 14 (2003) S246-249
39. Ha H., and Lee H.B. Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney. Nephrology (Carlton) 10 (2005) S7-S10 (Suppl.)
40. Agarwal R. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am. J. Physiol. Renal Physiol. 284 (2003) F863-869
41. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J. Am. Soc. Nephrol. 17 (2006) 17-25
42. Zhao W., Chen S.S., Chen Y., Ahokas R.A., and Sun Y. Kidney fibrosis in hypertensive rats: role of oxidative stress. Am. J. Nephrol. 28 (2008) 548-554
43. Djamali A., Vidyasagar A., Adulla M., Hullett D., and Reese S. Nox-2 is a modulator of fibrogenesis in kidney allografts. Am. J. Transplant 9 (2009) 74-82
44. Ogawa F., Shimizu K., Muroi E., Hara T., Hasegawa M., Takehara K., and Sato S. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology 45 (2006) 815-818
45. Murdoch C.E., Zhang M., Cave A.C., and Shah A.M. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc. Res. 71 (2006) 208-215
46. Sirker A., Zhang M., Murdoch C., and Shah A.M. Involvement of NADPH oxidases in cardiac remodelling and heart failure. Am. J. Nephrol. 27 (2007) 649-660
47. Sun Y. Oxidative stress and cardiac repair/remodeling following infarction. Am. J. Med. Sci. 334 (2007) 197-205
48. Aragno M., Mastrocola R., Alloatti G., Vercellinatto I., Bardini P., Geuna S., Catalano M.G., Danni O., and Boccuzzi G. Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinology 149 (2008) 380-388
49. Zhao W., Zhao T., Chen Y., Ahokas R.A., and Sun Y. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Mol. Cell. Biochem. 317 (2008) 43-50
50. Broekelmann T.J., Limper A.H., Colby T.V., and McDonald J.A. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl. Acad. Sci. USA 88 (1991) 6642-6646
51. Khalil N., O'Connor R.N., Flanders K.C., and Unruh H. TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. Am. J. Respir. Cell Mol. Biol. 14 (1996) 131-138
52. Jagirdar J., Lee T.C., Reibman J., Gold L.I., Aston C., Begin R., and Rom W.N. Immunohistochemical localization of transforming growth factor beta isoforms in asbestos-related diseases. Environ. Health Perspect. 105 Suppl. 5 (1997) 1197-1203
53. Bergeron A., Soler P., Kambouchner M., Loiseau P., Milleron B., Valeyre D., Hance A.J., and Tazi A. Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. Eur. Respir. J. 22 (2003) 69-76
54. Rimal B., Greenberg A.K., and Rom W.N. Basic pathogenetic mechanisms in silicosis: current understanding. Curr. Opin. Pulm. Med. 11 (2005) 169-173
55. Brook N.R., White, S. A., Waller J.R., Bicknell G.R., and Nicholson M.L. Fibrosis-associated gene expression in renal transplant glomeruli after acute renal allograft rejection. Br. J. Surg. 90 (2003) 1009-1014
56. Ali M.A., Koura B.A., el-Mashad N., and Zaghloul M.H. The Bcl-2 and TGF-beta1 levels in patients with chronic hepatitis C, liver cirrhosis and hepatocellular carcinoma. Egypt. J. Immunol. 11 (2004) 83-90
57. Bataller R., and Brenner D.A. Liver fibrosis. J. Clin. Invest. 115 (2005) 209-218
58. Tzortzaki E.G., Antoniou K.M., Zervou M.I., Lambiri I., Koutsopoulos A., Tzanakis N., Plataki M., Maltezakis G., Bouros D., and Siafakas N.M. Effects of antifibrotic agents on TGF-β1, CTGF and IFN-γ expression in patients with idiopathic pulmonary fibrosis. Respir. Med. 101 (2007) 1821-1829
59. Brosius F. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev. Endocr. Metab. Disord. 9 (2008) 245-254
60. Varga J. Systemic sclerosis: an update. Bull. NYU Hospital Joint Dis. 66 (2008) 198
61. Fahy R.J., Lichtenberger F., McKeegan C.B., Nuovo G.J., Marsh C.B., and Wewers M.D. The acute respiratory distress syndrome: a role for transforming growth factor-beta 1. Am. J. Respir. Cell Mol. Biol. 28 (2003) 499-503
62. Williams A.O., Flanders K.C., and Saffiotti U. Immunohistochemical localization of transforming growth factor-beta 1 in rats with experimental silicosis, alveolar type II hyperplasia, and lung cancer. Am. J. Pathol. 142 (1993) 1831-1840
63. Coker R.K., Laurent G.J., Shahzeidi S., Lympany P.A., du Bois R.M., Jeffery P.K., and McAnulty R.J. Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. Am. J. Pathol. 150 (1997) 981-991
64. Rube C.E., Uthe D., Schmid K.W., Richter K.D., Wessel J., Schuck A., Willich N., and Rube C. Dose-dependent induction of transforming growth factor beta (TGF-beta) in the lung tissue of fibrosis-prone mice after thoracic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 47 (2000) 1033-1042
65. Kumar R.K., Herbert C., and Foster P.S. Expression of growth factors by airway epithelial cells in a model of chronic asthma: regulation and relationship to subepithelial fibrosis. Clin. Exp. Allergy 34 (2004) 567-575
66. Ellmers L.J., Scott N.J.A., Medicherla S., Pilbrow A.P., Bridgman P.G., Yandle T.G., Richards A.M., Protter A.A., and Cameron V.A. Transforming growth factor-β blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction. Endocrinology 149 (2008) 5828-5834
67. Churg A., Zhou S., Preobrazhenska O., Tai H., Wang R., and Wright J.L. Expression of profibrotic mediators in small airways versus parenchyma after cigarette smoke exposure. Am. J. Respir. Cell Mol. Biol. 40 (2009) 268-276
68. Ng Y.Y., Chen Y.M., Tsai T.J., Lan X.R., Yang W.C., and Lan H.Y. Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats. Am. J. Nephrol. 29 (2009) 43-53
69. Sanderson N., Factor V., Nagy P., Kopp J., Kondaiah P., Wakefield L., Roberts A.B., Sporn M.B., and Thorgeirsson S.S. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc. Natl. Acad. Sci. USA 92 (1995) 2572-2576
70. Clouthier D.E., Comerford S.A., and Hammer R.E. Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. J. Clin. Invest. 100 (1997) 2697-2713
71. Mozes M.M., Bottinger E.P., Jacot T.A., and Kopp J.B. Renal expression of fibrotic matrix proteins and of transforming growth factor-beta (TGF-beta) isoforms in TGF-beta transgenic mice. J. Am. Soc. Nephrol. 10 (1999) 271-280
72. Hardie W.D., Le Cras T.D., Jiang K., Tichelaar J.W., Azhar M., and Korfhagen T.R. Conditional expression of transforming growth factor-alpha in adult mouse lung causes pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 286 (2004) L741-749
73. Lee C.G., Cho S.J., Kang M.J., Chapoval S.P., Lee P.J., Noble P.W., Yehualaeshet T., Lu B., Flavell R.A., Milbrandt J., Homer R.J., and Elias J.A. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J. Exp. Med. 200 (2004) 377-389
74. Vicencio A.G., Lee C.G., Cho S.J., Eickelberg O., Chuu Y., Haddad G.G., and Elias J.A. Conditional overexpression of bioactive transforming growth factor-beta1 in neonatal mouse lung: a new model for bronchopulmonary dysplasia?. Am. J. Respir. Cell Mol. Biol. 31 (2004) 650-656
75. Sime P.J., Xing Z., Graham F.L., Csaky K.G., and Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J. Clin. Invest. 100 (1997) 768-776
76. Kolb M., Bonniaud P., Galt T., Sime P.J., Kelly M.M., Margetts P.J., and Gauldie J. Differences in the fibrogenic response after transfer of active transforming growth factor-beta1 gene to lungs of "fibrosis-prone" and "fibrosis-resistant" mouse strains. Am. J. Respir. Cell Mol. Biol. 27 (2002) 141-150
77. Bonniaud P., Margetts P.J., Kolb M., Schroeder J.A., Kapoun A.M., Damm D., Murphy A., Chakravarty S., Dugar S., Higgins L., Protter A.A., and Gauldie J. Progressive transforming growth factor β1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am. J. Respir. Crit. Care Med. 171 (2005) 889-898
78. Margetts P.J., Bonniaud P., Liu L., Hoff C.M., Holmes C.J., West-Mays J.A., and Kelly M.M. Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum. J. Am. Soc. Nephrol. 16 (2005) 425-436
79. Giri S.N., Hyde D.M., and Hollinger M.A. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 48 (1993) 959-966
80. Higashiyama H., Yoshimoto D., Kaise T., Matsubara S., Fujiwara M., Kikkawa H., Asano S., and Kinoshita M. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Exp. Mol. Pathol. 83 (2007) 39-46
81. Yamaguchi Y., Mann D.M., and Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 346 (1990) 281-284
82. Wang Q., Wang Y., Hyde D.M., Gotwals P.J., Koteliansky V.E., Ryan S.T., and Giri S.N. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax 54 (1999) 805-812
83. Kolb M., Margetts P.J., Galt T., Sime P.J., Xing Z., Schmidt M., and Gauldie J. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am. J. Respir. Crit. Care Med. 163 (2001) 770-777
84. Kolb M., Margetts P.J., Sime P.J., and Gauldie J. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am. J. Physiol. Lung Cell Mol. Physiol. 280 (2001) L1327-1334
85. Yoo B.M., Yeo M., Oh T.Y., Choi J.H., Kim W.W., Kim J.H., Cho S.W., Kim S.J., and Hahm K.B. Amelioration of pancreatic fibrosis in mice with defective TGF-beta signaling. Pancreas 30 (2005) e71-79
86. Ambalavanan N., Nicola T., Hagood J., Bulger A., Serra R., Murphy-Ullrich J., Oparil S., and Chen Y.F. Transforming growth factor-beta signaling mediates hypoxia-induced pulmonary arterial remodeling and inhibition of alveolar development in newborn mouse lung. Am. J. Physiol. Lung Cell Mol. Physiol. 295 (2008) L86-95
87. Shibanuma M., Kuroki T., and Nose K. Release of H2O2 and phosphorylation of 30 kilodalton proteins as early responses of cell cycle-dependent inhibition of DNA synthesis by transforming growth factor beta 1. Cell Growth Differ. 2 (1991) 583-591
88. Thannickal V.J., Day R.M., Klinz S.G., Bastien M.C., Larios J.M., and Fanburg B.L. Ras-dependent and -independent regulation of reactive oxygen species by mitogenic growth factors and TGF-beta1. FASEB J. 14 (2000) 1741-1748
89. Thannickal V.J., and Fanburg B.L. Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor beta 1. J. Biol. Chem. 270 (1995) 30334-30338
90. Thannickal V.J., Hassoun P.M., White A.C., and Fanburg B.L. Enhanced rate of H2O2 release from bovine pulmonary artery endothelial cells induced by TGF-beta 1. Am. J. Physiol. 265 (1993) L622-626
91. Hu T., RamachandraRao S.P., Siva S., Valancius C., Zhu Y., Mahadev K., Toh I., Goldstein B.J., Woolkalis M., and Sharma K. Reactive oxygen species production via NADPH oxidase mediates TGF-{beta}-induced cytoskeletal alterations in endothelial cells. Am. J. Physiol. Renal Physiol. 289 (2005) F816-825
92. Yoon Y.S., Lee J.H., Hwang S.C., Choi K.S., and Yoon G. TGF beta1 induces prolonged mitochondrial ROS generation through decreased complex IV activity with senescent arrest in Mv1Lu cells. Oncogene 24 (2005) 1895-1903
93. Goettsch C., Goettsch W., Muller G., Seebach J., Schnittler H.J., and Morawietz H. Nox4 overexpression activates reactive oxygen species and p38 MAPK in human endothelial cells. Biochem. Biophys. Res. Commun. 380 (2009) 355-360
94. Murillo M.M., Carmona-Cuenca I., Del Castillo G., Ortiz C., Roncero C., Sanchez A., Fernandez M., and Fabregat I. Activation of NADPH oxidase by transforming growth factor-beta in hepatocytes mediates up-regulation of epidermal growth factor receptor ligands through a nuclear factor-kappaB-dependent mechanism. Biochem. J. 405 (2007) 251-259
95. Carmona-Cuenca I., Roncero C., Sancho P., Caja L., Fausto N., Fernandez M., and Fabregat I. Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. J. Hepatol. 49 (2008) 965-976
96. Sancho P., Bertran E., Caja L., Carmona-Cuenca I., Murillo M.M., and Fabregat I. The inhibition of the epidermal growth factor (EGF) pathway enhances TGF-beta-induced apoptosis in rat hepatoma cells through inducing oxidative stress coincident with a change in the expression pattern of the NADPH oxidases (NOX) isoforms. Biochim. Biophys. Acta 1793 (2009) 253-263
97. Sturrock A., Cahill B., Norman K., Huecksteadt T.P., Hill K., Sanders K., Karwande S.V., Stringham J.C., Bull D.A., Gleich M., Kennedy T.P., and Hoidal J.R. Transforming growth factor-beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 290 (2006) L661-673
98. Cucoranu I., Clempus R., Dikalova A., Phelan P.J., Ariyan S., Dikalov S., and Sorescu D. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ. Res. 97 (2005) 900-907
99. Albright C.D., Salganik R.I., Craciunescu C.N., Mar M.H., and Zeisel S.H. Mitochondrial and microsomal derived reactive oxygen species mediate apoptosis induced by transforming growth factor-beta1 in immortalized rat hepatocytes. J. Cell. Biochem. 89 (2003) 254-261
100. Herrera B., Murillo M.M., Alvarez-Barrientos A., Beltran J., Fernandez M., and Fabregat I. Source of early reactive oxygen species in the apoptosis induced by transforming growth factor-β in fetal rat hepatocytes. Free Radic. Biol. Med. 36 (2004) 16-26
101. Sturrock A., Huecksteadt T.P., Norman K., Sanders K., Murphy T.M., Chitano P., Wilson K., Hoidal J.R., and Kennedy T.P. Nox4 mediates TGF-beta1-induced retinoblastoma protein phosphorylation, proliferation, and hypertrophy in human airway smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 292 (2007) L1543-1555
102. Ismail S., Sturrock A., Wu P., Cahill B., Norman K., Huecksteadt T., Sanders K., Kennedy T., and Hoidal J. NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: the role of autocrine production of transforming growth factor-β1 and insulin-like growth factor binding protein-3. Am. J. Physiol. Lung Cell Mol. Physiol. 296 (2009) L489-499
103. Hecker L., Vittal R., Jones T., Jagirdar R., Luckhardt T.R., Horowitz J.C., Pennathur S., Martinez F.J., and Thannickal V.J. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 15 (2009) 1077-1081
104. Buul J.D.V., Fernandez-Borja M., Anthony E.C., and Hordijk P.L. Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxid. Redox Signaling 7 (2005) 308
105. Chen K., Kirber M.T., Xiao H., Yang Y., and Keaney Jr. J.F. Regulation of ROS signal transduction by NADPH oxidase 4 localization. J. Cell Biol. 181 (2008) 1129-1139
106. Helmcke I., Heumuller S., Tikkanen R., Schroder K., and Brandes R.P. Identification of structural elements in Nox1 and Nox4 controlling localization and activity. Antioxid. Redox Signaling 11 (2009) 1279-1287
107. Mittal M., Roth M., Konig P., Hofmann S., Dony E., Goyal P., Selbitz A.-C., Schermuly R.T., Ghofrani H.A., Kwapiszewska G., Kummer W., Klepetko W., Hoda M.A.R., Fink L., Hanze J., Seeger W., Grimminger F., Schmidt H.H.H.W., and Weissmann N. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ. Res. 101 (2007) 258-267
108. Pendyala S., Gorshkova I.A., Usatyuk P., He D., Pennathur A., Lambeth J.D., Thannickal V.J., and Natarajan V. Role of Nox4 and Nox2 in hyperoxia-induced reactive oxygen species generation and migration of human lung endothelial cells. Antioxid. Redox Signaling 11 (2009) 747-764
109. Kuroda J.K.N., Yamasaki T., Nakamura K.-i., Takeya R., Kuribayashi F., Imajoh-Ohmi S., Igarashi K., Shibata Y., Sueishi K., and Sumimoto H. The superoxide-producing NAD(P)H oxidase Nox4 in the nucleus of human vascular endothelial cells. Genes Cells 10 (2005) 1139-1151
110. Kayanoki Y., Fujii J., Suzuki K., Kawata S., Matsuzawa Y., and Taniguchi N. Suppression of antioxidative enzyme expression by transforming growth factor-beta 1 in rat hepatocytes. J. Biol. Chem 269 (1994) 15488-15492
111. Islam K.N., Kayanoki Y., Kaneto H., Suzuki K., Asahi M., Fujii J., and Taniguchi N. TGF-beta1 triggers oxidative modifications and enhances apoptosis in HIT cells through accumulation of reactive oxygen species by suppression of catalase and glutathione peroxidase. Free Radic. Biol. Med. 22 (1997) 1007-1017
112. Peltoniemi M., Kaarteenaho-Wiik R., Saily M., Sormunen R., Paakko P., Holmgren A., Soini Y., and Kinnula V.L. Expression of glutaredoxin is highly cell specific in human lung and is decreased by transforming growth factor-beta in vitro and in interstitial lung diseases in vivo. Hum. Pathol. 35 (2004) 1000-1007
113. Saharinen J., Taipale J., Monni O., and Keski-Oja J. Identification and characterization of a new latent transforming growth factor-beta-binding protein, LTBP-4. J. Biol. Chem. 273 (1998) 18459-18469
114. Todorovic V., Jurukovski V., Chen Y., Fontana L., Dabovic B., and Rifkin D.B. Latent TGF-β binding proteins. Int. J. Biochem. Cell Biol 37 (2005) 38-41
115. Koli K., Hyytiäinen M., Ryynänen M.J., and Keski-Oja J. Sequential deposition of latent TGF-β binding proteins (LTBPs) during formation of the extracellular matrix in human lung fibroblasts. Exp. Cell Res. 310 (2005) 370-382
116. Schultz-Cherry S., and Murphy-Ullrich J.E. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J. Cell Biol. 122 (1993) 923-932
117. Murphy-Ullrich J.E., and Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 11 (2000) 59-69
118. Munger J.S., Huang X., Kawakatsu H., Griffiths M.J., Dalton S.L., Wu J., Pittet J.F., Kaminski N., Garat C., Matthay M.A., Rifkin D.B., and Sheppard D. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96 (1999) 319-328
119. Mu D., Cambier S., Fjellbirkeland L., Baron J.L., Munger J.S., Kawakatsu H., Sheppard D., Broaddus V.C., and Nishimura S.L. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J. Cell Biol. 157 (2002) 493-507
120. Lyons R.M., Keski-Oja J., and Moses H.L. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J. Cell Biol. 106 (1988) 1659-1665
121. Taipale J., Lohi J., Saarinen J., Kovanen P.T., and Keski-Oja J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J. Biol. Chem. 270 (1995) 4689-4696
122. Taipale J., Koli K., and Keski-Oja J. Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J. Biol. Chem. 267 (1992) 25378-25384
123. Yu Q., and Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 14 (2000) 163-176
124. Barcellos-Hoff M., and Dix T. Redox-mediated activation of latent transforming growth factor-beta 1. Mol. Endocrinol. 10 (1996) 1077-1083
125. Vodovotz Y., Chesler L., Chong H., Kim S.J., Simpson J.T., DeGraff W., Cox G.W., Roberts A.B., Wink D.A., and Barcellos-Hoff M.H. Regulation of transforming growth factor beta1 by nitric oxide. Cancer Res. 59 (1999) 2142-2149
126. Pociask, D. A.; Sime, P. J.; Brody, A. R. Asbestos-derived reactive oxygen species activate TGF-β1. Lab. Invest. 84:1013-1023; 2004.
127. Wang L., Clutter S., Benincosa J., Fortney J., and Gibson L.F. Activation of transforming growth factor-β1/p38/Smad3 signaling in stromal cells requires reactive oxygen species-mediated MMP-2 activity during bone marrow damage. Stem Cells 23 (2005) 1122-1134
128. Amarnath S., Dong L., Li J., Wu Y., and Chen W. Endogenous TGF-beta activation by reactive oxygen species is key to Foxp3 induction in TCR-stimulated and HIV-1-infected human CD4+CD25- T cells. Retrovirology 4 (2007) 57
129. Wang H., and Kochevar I.E. Involvement of UVB-induced reactive oxygen species in TGF-β biosynthesis and activation in keratinocytes. Free Radic. Biol. Med. 38 (2005) 890-897
130. Jobling M.F., Mott J.D., Finnegan M.T., Jurukovski V., Erickson A.C., Walian P.J., Taylor S.E., Ledbetter S., Lawrence C.M., Rifkin D.B., and Barcellos-Hoff M.H. Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat. Res. 166 (2006) 839-848
131. Sullivan D.E., Ferris M., Pociask D., and Brody A.R. The latent form of TGFbeta(1) is induced by TNFalpha through an ERK specific pathway and is activated by asbestos-derived reactive oxygen species in vitro and in vivo. J. Immunotoxicol. 5 (2008) 145-149
132. Leonarduzzi G., Scavazza A., Biasi F., Chiarpotto E., Camandola S., Vogl S., Dargel R., and Poli G. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor β1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J. 11 (1997) 851-857
133. Bellocq A., Azoulay E., Marullo S., Flahault A., Fouqueray B., Philippe C., Cadranel J., and Baud L. Reactive oxygen and nitrogen intermediates increase transforming growth factor-beta1 release from human epithelial alveolar cells through two different mechanisms. Am. J. Respir. Cell Mol. Biol. 21 (1999) 128-136
134. Saito K., Ishizaka N., Aizawa T., Sata M., Iso-o N., Noiri E., Mori I., Ohno M., and Nagai R. Iron chelation and a free radical scavenger suppress angiotensin II-induced upregulation of TGF-beta1 in the heart. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H1836-1843
135. Shvedova A.A., Kisin E.R., Murray A.R., Kommineni C., Castranova V., Fadeel B., and Kagan V.E. Increased accumulation of neutrophils and decreased fibrosis in the lung of NADPH oxidase-deficient C57BL/6 mice exposed to carbon nanotubes. Toxicol. Appl. Pharmacol. 231 (2008) 235-240
136. Clark R.A., McCoy G.A., Folkvord J.M., and McPherson J.M. TGF-beta 1 stimulates cultured human fibroblasts to proliferate and produce tissue-like fibroplasia: a fibronectin matrix-dependent event. J. Cell. Physiol. 170 (1997) 69-80
137. Kay E.P., Lee M.S., Seong G.J., and Lee Y.G. TGF-beta stimulates cell proliferation via an autocrine production of FGF-2 in corneal stromal fibroblasts. Curr. Eye Res. 17 (1998) 286-293
138. Thannickal V.J., Aldweib K.D., Rajan T., and Fanburg B.L. Upregulated expression of fibroblast growth factor (FGF) receptors by transforming growth factor-β1 (TGF-β1) mediates enhanced mitogenic responses to FGFs in cultured human lung fibroblasts. Biochem. Biophys. Res. Commun. 251 (1998) 437-441
139. Strutz F., Zeisberg M., Renziehausen A., Raschke B., Becker V., van Kooten C., and Muller G. TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2). Kidney Int. 59 (2001) 579-592
140. Gallelli L., Falcone, D., Pelaia G., Renda T., Terracciano R., Malara N., Vatrella A., Sanduzzi A., D'Agostino B., Rossi F., Vancheri C., Maselli R., Marsico S.A., and Savino R. Interleukin-6 receptor superantagonist Sant7 inhibits TGF-β-induced proliferation of human lung fibroblasts. Cell Prolif. 41 (2008) 393-407
141. Cho J.W., Cha Y.C., and Lee K.S. AP-1 transcription factor decoy reduces the TGF-beta1-induced cell growth in scleroderma fibroblasts through inhibition of cyclin E. Oncol. Rep. 19 (2008) 737-741
142. Schmidt M., Sun G., Stacey M.A., Mori L., and Mattoli S. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J. Immunol. 171 (2003) 380-389
143. Iwano M., Plieth D., Danoff T.M., Xue C., Okada H., and Neilson E.G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110 (2002) 341-350
144. Strieter R.M., Keeley E.C., Hughes M.A., Burdick M.D., and Mehrad B. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J. Leukocyte Biol. (2009)
145. Xu J., Gonzalez E.T., Iyer S.S., Mac V., Mora A.L., Sutliff R.L., Reed A., Brigham K.L., Kelly P., and Rojas M. Use of senescence-accelerated mouse model in bleomycin-induced lung injury suggests that bone marrow-derived cells can alter the outcome of lung injury in aged mice. J. Gerontol. A Biol. Sci. Med. Sci. 64A (2009) 731-739
146. Abe R., Donnelly S.C., Peng T., Bucala R., and Metz C.N. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol. 166 (2001) 7556-7562
147. Quan T.E., Cowper S.E., and Bucala R. The role of circulating fibrocytes in fibrosis. Curr. Rheumatol. Rep. 8 (2006) 145-150
148. Masszi A., Fan L., Rosivall L., McCulloch C.A., Rotstein O.D., Mucsi I., and Kapus A. Integrity of cell-cell contacts is a critical regulator of TGF-beta 1-induced epithelial-to-myofibroblast transition: role for beta-catenin. Am. J. Pathol. 165 (2004) 1955-1967
149. Zavadil J., Cermak L., Soto-Nieves N., and Bottinger E.P. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J. 23 (2004) 1155-1165
150. Nawshad A., Lagamba D., Polad A., and Hay E.D. Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. Cells Tissues Organs 179 (2005) 11-23
151. Han G., Lu S.L., Li A.G., He W., Corless C.L., Kulesz-Martin M., and Wang X.J. Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J. Clin. Invest. 115 (2005) 1714-1723
152. Radisky D.C., Levy D.D., Littlepage L.E., Liu H., Nelson C.M., Fata J.E., Leake D., Godden E.L., Albertson D.G., Nieto M.A., Werb Z., and Bissell M.J. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436 (2005) 123-127
153. Ward C., Forrest I.A., Murphy D.M., Johnson G.E., Robertson H., Cawston T.E., Fisher A.J., Dark J.H., Lordan J.L., Kirby J.A., and Corris P.A. Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients. Thorax 60 (2005) 865-871
154. Willis B.C., Liebler J.M., Luby-Phelps K., Nicholson A.G., Crandall E.D., du Bois R.M., and Borok Z. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol. 166 (2005) 1321-1332
155. Willis B.C., duBois R.M., and Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc. Am. Thorac. Soc. 3 (2006) 377-382
156. Slattery C., Campbell E., McMorrow T., and Ryan M.P. Cyclosporine A-induced renal fibrosis: a role for epithelial-mesenchymal transition. Am. J. Pathol. 167 (2005) 395-407
157. Saika S., Kono-Saika S., Ohnishi Y., Sato M., Muragaki Y., Ooshima A., Flanders K.C., Yoo J., Anzano M., Liu C.Y., Kao W.W., and Roberts A.B. Smad3 signaling is required for epithelial-mesenchymal transition of lens epithelium after injury. Am. J. Pathol. 164 (2004) 651-663
158. Kim K.K., Kugler M.C., Wolters P.J., Robillard L., Galvez M.G., Brumwell A.N., Sheppard D., and Chapman H.A. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. USA 103 (2006) 13180-13185
159. Wu Z., Yang L., Cai L., Zhang M., Cheng X., Yang X., and Xu J. Detection of epithelial to mesenchymal transition in airways of a bleomycin induced pulmonary fibrosis model derived from an alpha-smooth muscle actin-Cre transgenic mouse. Respir. Res. 8 (2007) 1
160. Zeisberg E.M., Potenta S.E., Sugimoto H., Zeisberg M., and Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 19 (2008) 2282-2287
161. Zeisberg E.M., Tarnavski O., Zeisberg M., Dorfman A.L., McMullen J.R., Gustafsson E., Chandraker A., Yuan X., Pu W.T., Roberts A.B., Neilson E.G., Sayegh M.H., Izumo S., and Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 13 (2007) 952-961
162. Sumioka T., Ikeda K., Okada Y., Yamanaka O., Kitano A., and Saika S. Inhibitory effect of blocking TGF-beta/Smad signal on injury-induced fibrosis of corneal endothelium. Mol. Vision 14 (2008) 2272-2281
163. Yao H.W., Xie Q.M., Chen J.Q., Deng Y.M., and Tang H.F. TGF-beta1 induces alveolar epithelial to mesenchymal transition in vitro. Life Sci. 76 (2004) 29-37
164. Kasai H., Allen J.T., Mason R.M., Kamimura T., and Zhang Z. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir. Res. 6 (2005) 56
165. Vyas-Read S., Shaul P.W., Yuhanna I.S., and Willis B.C. Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 293 (2007) L212-L221
166. Jain R., Shaul P.W., Borok Z., and Willis B.C. Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1. Am. J. Respir. Cell Mol. Biol. 37 (2007) 38-47
167. Kitao A., Sato Y., Sawada-Kitamura S., Harada K., Sasaki M., Morikawa H., Shiomi S., Honda M., Matsui O., and Nakanuma Y. Endothelial to mesenchymal transition via transforming growth factor-β1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension. Am. J. Pathol. 175 (2009) 616-626
168. Zhang A., Jia Z., Guo X., and Yang T. Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin. Am. J. Physiol. Renal Physiol. 293 (2007) F723-731
169. Zeng R., Yao Y., Han M., Zhao X., Liu X.C., Wei J., Luo Y., Zhang J., Zhou J., Wang S., Ma D., and Xu G. Biliverdin reductase mediates hypoxia-induced EMT via PI3-kinase and Akt. J. Am. Soc. Nephrol. 19 (2008) 380-387
170. Rhyu D.Y., Yang Y., Ha H., Lee G.T., Song J.S., Uh S.T., and Lee H.B. Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J. Am. Soc. Nephrol. 16 (2005) 667-675
171. Sato M., Muragaki Y., Saika S., Roberts A.B., and Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest. 112 (2003) 1486-1494
172. Phanish M.K., Wahab N.A., Colville-Nash P., Hendry B.M., and Dockrell M.E. The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem. J. 393 (2006) 601-607
173. Yang J., Dai C., and Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J. Am. Soc. Nephrol. 16 (2005) 68-78
174. Ivanova L., Butt M.J., and Matsell D.G. Mesenchymal transition in kidney collecting duct epithelial cells. Am. J. Physiol. Renal Physiol. 294 (2008) F1238-1248
175. Grande M., Franzen A., Karlsson J.O., Ericson L.E., Heldin N.E., and Nilsson M. Transforming growth factor-beta and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes. J. Cell Sci. 115 (2002) 4227-4236
176. Bakin A.V., Tomlinson A.K., Bhowmick N.A., Moses H.L., and Arteaga C.L. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 275 (2000) 36803-36810
177. Bakin A.V., Rinehart C., Tomlinson A.K., and Arteaga C.L. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J. Cell Sci. 115 (2002) 3193-3206
178. Cho H.J., Baek K.E., Saika S., Jeong M.J., and Yoo J. Snail is required for transforming growth factor-β-induced epithelial-mesenchymal transition by activating PI3 kinase/Akt signal pathway. Biochem. Biophys. Res. Commun. 353 (2007) 337-343
179. Yao K., Ye P.P., Tan J., Tang X.J., and Shen Tu X.C. Involvement of PI3K/Akt pathway in TGF-beta2-mediated epithelial mesenchymal transition in human lens epithelial cells. Ophthalmic Res. 40 (2008) 69-76
180. Canbay A., Higuchi H., Bronk S.F., Taniai M., Sebo T.J., and Gores G.J. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 123 (2002) 1323-1330
181. Canbay A., Feldstein A., Baskin-Bey E., Bronk S.F., and Gores G.J. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J. Pharmacol. Exp. Ther. 308 (2004) 1191-1196
182. Kasper M., Seidel D., Knels L., Morishima N., Neisser A., Bramke S., and Koslowski R. Early signs of lung fibrosis after in vitro treatment of rat lung slices with CdCl2 and TGF-β1. Histochem. Cell Biol. 121 (2004) 131-140
183. Herrera B., Alvarez A.M., Sanchez A., Fernandez M., Roncero C., Benito M., and Fabregat I. Reactive oxygen species (ROS) mediates the mitochondrial-dependent apoptosis induced by transforming growth factor (beta) in fetal hepatocytes. FASEB J. 15 (2001) 741-751
184. Waghray M., Cui Z., Horowitz J.C., Subramanian I.M., Martinez F.J., Toews G.B., and Thannickal V.J. Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J. 19 (2005) 854-856
185. Yao K., Tan J., Gu W.-Z., Ye P.-P., and Wang K.-J. Reactive oxygen species mediates the apoptosis induced by transforming growth factor β2 in human lens epithelial cells. Biochem. Biophys. Res. Commun. 354 (2007) 278-283
186. Meindl-Beinker N.M. S. D. Transforming growth factor-β and hepatocyte transdifferentiation in liver fibrogenesis. J. Gastroenterol. Hepatol. 23 (2008) S122-S127
187. Garcia-Trevijano E.R., Iraburu M.J., Fontana L., Dominguez-Rosales J.A., Auster A., Covarrubias-Pinedo A., and Rojkind M. Transforming growth factor beta1 induces the expression of alpha1(I) procollagen mRNA by a hydrogen peroxide-C/EBPbeta-dependent mechanism in rat hepatic stellate cells. Hepatology 29 (1999) 960-970
188. Cao Q., Mak K.M., and Lieber C.S. DLPC decreases TGF-beta 1-induced collagen mRNA by inhibiting p38 MAPK in hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 283 (2002) G1051-1061
189. Gooch J.L., Gorin Y., Zhang B.X., and Abboud H.E. Involvement of calcineurin in transforming growth factor-beta-mediated regulation of extracellular matrix accumulation. J. Biol. Chem. 279 (2004) 15561-15570
190. Jiang Z., Seo J.Y., Ha H., Lee E.A., Kim Y.S., Han D.C., Uh S.T., Park C.S., and Lee H.B. Reactive oxygen species mediate TGF-β1-induced plasminogen activator inhibitor-1 upregulation in mesangial cells. Biochem. Biophys. Res. Commun. 309 (2003) 961-966
191. Li W.Q., Qureshi H.Y., Liacini A., Dehnade F., and Zafarullah M. Transforming growth factor β1 induction of tissue inhibitor of metalloproteinases 3 in articular chondrocytes is mediated by reactive oxygen species. Free Radic. Biol. Med. 37 (2004) 196-207
192. Vayalil P.K., Olman M., Murphy-Ullrich J.E., Postlethwait E.M., and Liu R.M. Glutathione restores collagen degradation in TGF-beta-treated fibroblasts by blocking plasminogen activator inhibitor-1 expression and activating plasminogen. Am. J. Physiol. Lung Cell Mol. Physiol. 289 (2005) L937-945
193. Vayalil P.K., Iles K.E., Choi J., Yi A.-K., Postlethwait E.M., and Liu R.-M. Glutathione suppresses TGF-β-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter. Am. J. Physiol. Lung Cell Mol. Physiol. 293 (2007) L1281-1292
194. Laurent G.J. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am. J. Physiol. 252 (1987) C1-9
195. Arthur M.J. Degradation of matrix proteins in liver fibrosis. Pathol. Res. Pract. 190 (1994) 825-833
196. Davidson J.M. Biochemistry and turnover of lung interstitium. Eur. Respir. J. 3 (1990) 1048-1063
197. Liu R.M. Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis. Antioxid. Redox Signaling 10 (2008) 303-319
198. Kutz S.M., Hordines J., McKeown-Longo P.J., and Higgins P.J. TGF-beta1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. J. Cell Sci. 114 (2001) 3905-3914
199. Wang L., Ma R., Flavell R.A., and Choi M.E. Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for activation of p38alpha and p38delta MAPK isoforms by TGF-beta 1 in murine mesangial cells. J. Biol. Chem. 277 (2002) 47257-47262
200. Shi Y., and Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113 (2003) 685-700
201. Woodward R.N., Finn A.V., and Dichek D.A. Identification of intracellular pathways through which TGF-β1 upregulates PAI-1 expression in endothelial cells. Atherosclerosis 186 (2006) 92-100
202. Guo B., Inoki K., Isono M., Mori H., Kanasaki K., Sugimoto T., Akiba S., Sato T., Yang B., Kikkawa R., Kashiwagi A., Haneda M., and Koya D. MAPK/AP-1-dependent regulation of PAI-1 gene expression by TGF-β in rat mesangial cells. Kidney Int. 68 (2005) 972-984
203. Salmeen A., Andersen J.N., Myers M.P., Meng T.C., Hinks J.A., Tonks N.K., and Barford D. Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature 423 (2003) 769-773
204. Barrett W.C., DeGnore J.P., Konig S., Fales H.M., Keng Y.F., Zhang Z.Y., Yim M.B., and Chock P.B. Regulation of PTP1B via glutathionylation of the active site cysteine 215. Biochemistry 38 (1999) 6699-6705
205. Denu J.M., and Tanner K.G. Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry 37 (1998) 5633-5642
206. Denu J.M., and Tanner K.G. Redox regulation of protein tyrosine phosphatases by hydrogen peroxide: detecting sulfenic acid intermediates and examining reversible inactivation. Methods Enzymol. 348 (2002) 297-305
207. Dixon D.P., Fordham-Skelton A.P., and Edwards R. Redox regulation of a soybean tyrosine-specific protein phosphatase. Biochemistry 44 (2005) 7696-7703
208. Rao R.K., and Clayton L.W. Regulation of protein phosphatase 2A by hydrogen peroxide and glutathionylation. Biochem. Biophys. Res. Commun. 293 (2002) 610-616
209. Foley T.D., Armstrong J.J., and Kupchak B.R. Identification and H2O2 sensitivity of the major constitutive MAPK phosphatase from rat brain. Biochem. Biophys. Res. Commun. 315 (2004) 568-574
210. Foley T.D., and Kintner M.E. Brain PP2A is modified by thiol-disulfide exchange and intermolecular disulfide formation. Biochem. Biophys. Res. Commun. 330 (2005) 1224-1229
211. Levinthal D.J., and Defranco D.B. Reversible oxidation of ERK-directed protein phosphatases drives oxidative toxicity in neurons. J. Biol. Chem. 280 (2005) 5875-5883
212. Kamata H., Honda S., Maeda S., Chang L., Hirata H., and Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120 (2005) 649-661
213. Foley T., Petro L., Stredny C., and Coppa T. Oxidative inhibition of protein phosphatase 2A activity: role of catalytic subunit disulfides. Neurochem. Res. 32 (2007) 1957-1964
214. Fontenay M., Bryckaert M., and Tobelem G. Transforming growth factor-beta 1 inhibitory effect of platelet-derived growth factor-induced signal transduction on human bone marrow fibroblasts: possible involvement of protein phosphatases. J. Cell Physiol. 152 (1992) 507-519
215. Mire-Sluis A.R., Page L., Wadhwa M., and Thorpe R. Transforming growth factor-beta 1 blocks interleukin 4 induced cell proliferation by inhibiting a protein tyrosine phosphatase essential for signal transduction. Cytokine 6 (1994) 389-398
216. Petritsch C., Beug H., Balmain A., and Oft M. TGF-beta inhibits p70 S6 kinase via protein phosphatase 2A to induce G(1) arrest. Genes Dev. 14 (2000) 3093-3101
217. Young M.R. Tumor-derived prostaglandin E2 and transforming growth factor-beta stimulate endothelial cell motility through inhibition of protein phosphatase-2A and involvement of PTEN and phosphatidylinositide 3-kinase. Angiogenesis 7 (2004) 123-131
218. Lires-Deán M., Caramés B., Cillero-Pastor B., Galdo F., López-Armada M.J., and Blanco F.J. Anti-apoptotic effect of transforming growth factor-β1 on human articular chondrocytes: role of protein phosphatase 2A. Osteoarthritis Cartilage 16 (2008) 1370-1378
219. Kim S.I., Kwak J.H., Wang L., and Choi M.E. Protein phosphatase 2A is a negative regulator of transforming growth factor-β1-induced TAK1 activation in mesangial cells. J. Biol. Chem. 283 (2008) 10753-10763
220. Ebert M.P.A., Fei G., Schandl L., Mawrin C., Dietzmann K., Herrera P., Friess H., Gress T.M., and Malfertheiner P. Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. Br. J. Cancer 86 (2002) 257-262
221. Chow J.Y.C., Dong H., Quach K.T., Van Nguyen P.N., Chen K., and Carethers J.M. TGF-β mediates PTEN suppression and cell motility through calcium-dependent PKC-α activation in pancreatic cancer cells. Am. J. Physiol. Gastrointest. Liver Physiol. 294 (2008) G899-905
222. Li D.M., and Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 57 (1997) 2124-2129
223. Rocic P., and Lucchesi P.A. NAD(P)H oxidases and TGF-β-induced cardiac fibroblast differentiation: Nox-4 gets Smad. Circ. Res. 97 (2005) 850-852
224. Kretzschmar M., Doody J., Timokhina I., and Massague J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev. 13 (1999) 804-816
225. Mori S., Matsuzaki K., Yoshida K., Furukawa F., Tahashi Y., Yamagata H., Sekimoto G., Seki T., Matsui H., Nishizawa M., Fujisawa J., and Okazaki K. TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 23 (2004) 7416-7429
226. Kamaraju A.K., and Roberts A.B. Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J. Biol. Chem. 280 (2005) 1024-1036
227. Javelaud D., and Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 24 (2005) 5742-5750
228. Yingling J.M., Datto M.B., Wong C., Frederick J.P., Liberati N.T., and Wang X.F. Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein. Mol. Cell. Biol. 17 (1997) 7019-7028
229. Sano Y., Harada J., Tashiro S., Gotoh-Mandeville R., Maekawa T., and Ishii S. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling. J. Biol. Chem. 274 (1999) 8949-8957
230. Hua X., Liu X., Ansari D.O., and Lodish H.F. Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev. 12 (1998) 3084-3095
231. Liu P., Zhang C., Feng J.B., Zhao Y.X., Wang X.P., Yang J.M., Zhang M.X., Wang X.L., and Zhang Y. Cross talk among Smad, MAPK, and integrin signaling pathways enhances adventitial fibroblast functions activated by transforming growth factor-β1 and inhibited by Gax. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 725-731
232. Biteau B., Labarre J., and Toledano M.B. ATP-dependent reduction of cysteine-sulphinic acid by S. cerevisiae sulphiredoxin. Nature 425 (2003) 980-984
233. Basu M.K., and Koonin E.V. Evolution of eukaryotic cysteine sulfinic acid reductase, sulfiredoxin (Srx), from bacterial chromosome partitioning protein ParB. Cell Cycle 4 (2005) 947-952
234. Rhee S.G., Jeong W., Chang T.S., and Woo H.A. Sulfiredoxin, the cysteine sulfinic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism of action, and biological significance. Kidney Int. Suppl. (2007) S3-S8
235. Jonsson T.J., Murray M.S., Johnson L.C., and Lowther W.T. Reduction of cysteine sulfinic acid in peroxiredoxin by sulfiredoxin proceeds directly through a sulfinic phosphoryl ester intermediate. J. Biol. Chem. 283 (2008) 23846-23851
236. Noh Y.H., Baek J.Y., Jeong W., Rhee S.G., and Chang T.-S. Sulfiredoxin translocation into mitochondria plays a crucial role in reducing hyperoxidized peroxiredoxin III. J. Biol. Chem. 284 (2009) 8470-8477
237. Shelton M.D., Chock P.B., and Mieyal J.J. Glutaredoxin: role in reversible protein S-glutathionylation and regulation of redox signal transduction and protein translocation. Antioxid. Redox Signaling 7 (2005) 348-366
238. Gallogly M.M., and Mieyal J.J. Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. Curr. Opin. Pharmacol. 7 (2007) 381-391
239. Mieyal J.J., Gallogly M.M., Qanungo S., Sabens E.A., and Shelton M.D. Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid. Redox Signaling 10 (2008) 1941-1988
240. Findlay V.J., Townsend D.M., Morris T.E., Fraser J.P., He L., and Tew K.D. A novel role for human sulfiredoxin in the reversal of glutathionylation. Cancer Res. 66 (2006) 6800-6806
241. Park J.W., Mieyal J.J., Rhee S.G., and Chock P.B. Deglutathionylation of 2-Cys peroxiredoxin is specifically catalyzed by sulfiredoxin. J. Biol. Chem. 284 (2009) 23364-23374
242. Lee S.R., Kwon K.S., Kim S.R., and Rhee S.G. Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J. Biol. Chem. 273 (1998) 15366-15372
243. Klatt P., and Lamas S. Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress. Eur. J. Biochem. 267 (2000) 4928-4944
244. Humphries K.M., Juliano C., and Taylor S.S. Regulation of cAMP-dependent protein kinase activity by glutathionylation. J. Biol. Chem. 277 (2002) 43505-43511
245. Lee S.R., Yang K.S., Kwon J., Lee C., Jeong W., and Rhee S.G. Reversible inactivation of the tumor suppressor PTEN by H2O2. J. Biol. Chem. 277 (2002) 20336-20342
246. Kwon J., Lee S.R., Yang K.S., Ahn Y., Kim Y.J., Stadtman E.R., and Rhee S.G. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc. Natl. Acad. Sci. USA 101 (2004) 16419-16424
247. Rahman I., Biswas S.K., Jimenez L.A., Torres M., and Forman H.J. Glutathione, stress responses, and redox signaling in lung inflammation. Antioxid. Redox Signaling 7 (2005) 42-59
248. Vogelmann R., Nguyen-Tat M.D., Giehl K., Adler G., Wedlich D., and Menke A. TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN. J. Cell Sci. 118 (2005) 4901-4912
249. Okamoto T., Akaike T., Sawa T., Miyamoto Y., van der Vliet A., and Maeda H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J. Biol. Chem. 276 (2001) 29596-29602
250. Davis D.A., Dorsey K., Wingfield P.T., Stahl S.J., Kaufman J., Fales H.M., and Levine R.L. Regulation of HIV-1 protease activity through cysteine modification. Biochemistry 35 (1996) 2482-2488
251. Davis D.A., Newcomb F.M., Starke D.W., Ott D.E., Mieyal J.J., and Yarchoan R. Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro. J. Biol. Chem. 272 (1997) 25935-25940
252. Dafre A.L., Sies H., and Akerboom T. Protein S-thiolation and regulation of microsomal glutathione transferase activity by the glutathione redox couple. Arch. Biochem. Biophys. 332 (1996) 288-294
253. Schafer F.Q., and Buettner G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 30 (2001) 1191-1212
254. Thomas J.A., Poland B., and Honzatko R. Protein sulfhydryls and their role in the antioxidant function of protein S-thiolation. Arch. Biochem. Biophys. 319 (1995) 1-9
255. Cotgreave I.A., and Gerdes R.G. Recent trends in glutathione biochemistry-glutathione-protein interactions: a molecular link between oxidative stress and cell proliferation?. Biochem. Biophys. Res. Commun. 242 (1998) 1-9
256. Ghezzi P. Regulation of protein function by glutathionylation. Free Radic. Res. 39 (2005) 573-580
257. Biswas S., Chida A.S., and Rahman I. Redox modifications of protein-thiols: emerging roles in cell signaling. Biochem. Pharmacol. 71 (2006) 551-564
258. Meister A. On the cycles of glutathione metabolism and transport. Curr. Top. Cell Regul. 18 (1981) 21-58
259. Roum J.H., Buhl R., McElvany N.G., Borok Z., and Crystal R.G. Systemic deficiency of glutathione in cystic fibrosis. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 75 (1993) 2419-2424
260. Tirouvanziam R., Conrad C.K., Bottiglieri T., Herzenberg L.A., and Moss R.B. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc. Natl. Acad. Sci. USA 103 (2006) 4628-4633
261. Rahman I., Skwarska E., Henry M., Davis M., O'Connor C.M., FitzGerald M.X., Greening A., and MacNee W. Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic. Biol. Med. 27 (1999) 60-68
262. Pacht E.R., Timerman A.P., Lykens M.G., and Merola A.J. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest 100 (1991) 1397-1403
263. Bunnell E., and Pacht E.R. Oxidized glutathione is increased in the alveolar fluid of patients with the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 148 (1993) 1174-1178
264. Laurent T., Markert M., Feihl F., Schaller M.D., and Perret C. Oxidant-antioxidant balance in granulocytes during ARDS: effect of N-acetylcysteine. Chest 109 (1996) 163-166
265. Bernard G.R., Wheeler A.P., Arons M.M., Morris P.E., Paz H.L., Russell J.A., and Wright P.E. A trial of antioxidants N-acetylcysteine and procysteine in ARDS: the Antioxidant in ARDS Study Group. Chest 112 (1997) 164-172
266. Soltan-Sharifi M.S., Mojtahedzadeh M., Najafi A., Reza Khajavi M., Reza Rouini M., Moradi M., Mohammadirad A., and Abdollahi M. Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanisms. Hum. Exp. Toxicol. 26 (2007) 697-703
267. Cantin A.M., Hubbard R.C., and Crystal R.G. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 139 (1989) 370-372
268. Borok Z., Grimes G.J., Buhl R., Bokser A., Hubbard R.C., Holroyd K., Roum J.H., Czerski D.B., Cantin A.M., and Crystal R.G. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet 338 (1991) 215-216
269. Meyer A., Buhl R., and Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur. Respir. J. 7 (1994) 431-436
270. Behr J., Maier K., Degenkolb B., Krombach F., and Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med.156 (1997) 1897-1901
271. Behr J., Degenkolb B., Krombach F., and Vogelmeier C. Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine. Eur. Respir. J. 19 (2002) 906-911
272. Montaldo C., Cannas E., Ledda M., Rosetti L., Congiu L., and Atzori L. Bronchoalveolar glutathione and nitrite/nitrate in idiopathic pulmonary fibrosis and sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 19 (2002) 54-58
273. Beeh K.M., Beier J., Haas I.C., Kornmann O., Micke P., and Buhl R. Glutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 19 (2002) 1119-1123
274. Boots A.W., Drent M., Swennen E.L.R., Moonen H.J.J., Bast A., and Haenen G.R.M.M. Antioxidant status associated with inflammation in sarcoidosis: a potential role for antioxidants. Respir. Med. 103 (2009) 364-372
275. Brown D.M., Beswick P.H., Bell K.S., and Donaldson K. Depletion of glutathione and ascorbate in lung lining fluid by respirable fibres. Ann. Occup. Hyg. 44 (2000) 101-108
276. Orman A., Kahraman A., Çakar H., Ellidokuz H., and Serteser M. Plasma malondialdehyde and erythrocyte glutathione levels in workers with cement dust-exposure silicosis. Toxicology 207 (2005) 15-20
277. Bianchi G., Bugianesi E., Ronchi M., Fabbri A., Zoli M., and Marchesini G. Glutathione kinetics in normal man and in patients with liver cirrhosis. J. Hepatol. 26 (1997) 606-613
278. Aboutwerat A., Pemberton P.W., Smith A., Burrows P.C., McMahon R.F.T., Jain S.K., and Warnes T.W. Oxidant stress is a significant feature of primary biliary cirrhosis. Biochim. Biophys. Acta 1637 (2003) 142-150
279. Loguercio C., and Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic. Biol. Med. 34 (2003) 1-10
280. Czeczot H., Scibior D., Skrzycki M., and Podsiad M. Glutathione and GSH-dependent enzymes in patients with liver cirrhosis and hepatocellular carcinoma. Acta Biochim. Pol. 53 (2006) 237-242
281. Bandara P.J.G., McCaughan G., Naidoo D., Lux O., Salonikas C., Kench J., Byth K., and Farrell G.C. Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C. Liver Int. 25 (2005) 518-526
282. Marotta F., Yoshida C., Barreto R., Naito Y., and Packer L. Oxidative-inflammatory damage in cirrhosis: effect of vitamin E and a fermented papaya preparation. J. Gastroenterol. Hepatol. 22 (2007) 697-703
283. Osman H., Gabr O., Lotfy S., and Gabr S. Serum levels of bcl-2 and cellular oxidative stress in patients with viral hepatitis. Indian J. Med. Microbiol. 25 (2007) 323-329
284. Joshi P.C., and Guidot D.M. The alcoholic lung: epidemiology, pathophysiology, and potential therapies. Am. J. Physiol. Lung Cell Mol. Physiol. 292 (2007) L813-L823
285. Ma J.Y., Barger M.W., Hubbs A.F., Castranova V., Weber S.L., and Ma J.K. Use of tetrandrine to differentiate between mechanisms involved in silica-versus bleomycin-induced fibrosis. J. Toxicol. Environ. Health A 57 (1999) 247-266
286. Candan F., and Alagozlu H. Captopril inhibits the pulmonary toxicity of paraquat in rats. Hum. Exp. Toxicol. 20 (2001) 637-641
287. Arslan S.O., Zerin M., Vural H., and Coskun A. The effect of melatonin on bleomycin-induced pulmonary fibrosis in rats. J. Pineal Res. 32 (2002) 21-25
288. Nieto N., and Cederbaum A.I. S-adenosylmethionine blocks collagen I production by preventing transforming growth factor-β induction of the COL1A2 promoter. J. Biol. Chem. 280 (2005) 30963-30974
289. Atzori L., Chua F., Dunsmore S.E., Willis D., Barbarisi M., McAnulty R.J., and Laurent G.J. Attenuation of bleomycin induced pulmonary fibrosis in mice using the heme oxygenase inhibitor Zn-deuteroporphyrin IX-2,4-bisethylene glycol. Thorax 59 (2004) 217-223
290. El-Medany A., Hagar H.H., Moursi M., At Muhammed R., El-Rakhawy F.I., and El-Medany G. Attenuation of bleomycin-induced lung fibrosis in rats by mesna. Eur. J. Pharmacol. 509 (2005) 61-70
291. Boyaci{dotless} H., Maral H., Turan G., Başyiǧit İ., Dillioǧlugil M., Yi{dotless}ldi{dotless}z F., Tugay M., Pala A., and Erçin C. Effects of erdosteine on bleomycin-induced lung fibrosis in rats. Mol. Cell. Biochem. 281 (2006) 129-137
292. Deger Y.F.Y., Ertekin A., Mert N., Dede S., and Mert H. Protective effect of alpha-tocopherol on oxidative stress in experimental pulmonary fibrosis in rats. Cell Biochem. Funct. 25 (2007) 633-637
293. Arafa H.M.M., Abdel-Wahab M.H., El-Shafeey M.F., Badary O.A., and Hamada F.M.A. Anti-fibrotic effect of meloxicam in a murine lung fibrosis model. Eur. J. Pharmacol. 564 (2007) 181-189
294. Hettiarachchi J., and Fernando S.S. Pulmonary fibrosis following paraquat poisoning. Ceylon Med. J. 33 (1988) 141-142
295. Ghazi-Khansari M., Mohammadi-Karakani A., Sotoudeh M., Mokhtary P., Pour-Esmaeil E., and Maghsoud S. Antifibrotic effect of captopril and enalapril on paraquat-induced lung fibrosis in rats. J. Appl. Toxicol. 27 (2007) 342-349
296. Abidi P., Afaq F., Arif J.M., Lohani M., and Rahman Q. Chrysotile-mediated imbalance in the glutathione redox system in the development of pulmonary injury. Toxicol. Lett. 106 (1999) 31-39
297. Lukivskaya O., Zavodnik L., Knas M., and Buko V. Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis. Adv. Med. Sci. 51 (2006) 54-59
298. Fernandez-Checa J.C., Colell A., and Garcia-Ruiz C. S-Adenosyl-l-methionine and mitochondrial reduced glutathione depletion in alcoholic liver disease. Alcohol 27 (2002) 179-183
299. Purucker E., Wernze W., and Krandik G. Glutathione in plasma, liver, and kidney in the development of CCl4-induced cirrhosis of the rat. Res. Exp. Med. (Berlin) 195 (1995) 193-199
300. Cabre M., Camps J., Paternain J.L., Ferre N., and Joven J. Time-course of changes in hepatic lipid peroxidation and glutathione metabolism in rats with carbon tetrachloride-induced cirrhosis. Clin. Exp. Pharmacol. Physiol. 27 (2000) 694-699
301. Kondou H., Mushiake S., Etani Y., Miyoshi Y., Michigami T., and Ozono K. A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo. J. Hepatol. 39 (2003) 742-748
302. Tahan V., Ozaras R., Canbakan B., Uzun H., Aydin S., Yildirim B., Aytekin H., Ozbay G., Mert A., and Senturk H. Melatonin reduces dimethylnitrosamine-induced liver fibrosis in rats. J. Pineal Res. 37 (2004) 78-84
303. Vendemiale G., Grattagliano I., Altomare E., Serviddio G., Portincasa P., Prigigallo F., and Palasciano G. Mitochondrial oxidative damage and myocardial fibrosis in rats chronically intoxicated with moderate doses of ethanol. Toxicol. Lett. 123 (2001) 209-216
304. White A.C., Das S.K., and Fanburg B.L. Reduction of glutathione is associated with growth restriction and enlargement of bovine pulmonary artery endothelial cells produced by transforming growth factor-beta 1. Am. J. Respir. Cell Mol. Biol. 6 (1992) 364-368
305. Sanchez A., Alvarez A.M., Benito M., and Fabregat I. Apoptosis induced by transforming growth factor-beta in fetal hepatocyte primary cultures: involvement of reactive oxygen intermediates. J. Biol. Chem. 271 (1996) 7416-7422
306. Sanchez A., Alvarez A.M., Benito M., and Fabregat I. Cycloheximide prevents apoptosis, reactive oxygen species production, and glutathione depletion induced by transforming growth factor beta in fetal rat hepatocytes in primary culture. Hepatology 26 (1997) 935-943
307. Arsalane K., Dubois C.M., Muanza T., Begin R., Boudreau F., Asselin C., and Cantin A.M. Transforming growth factor-beta1 is a potent inhibitor of glutathione synthesis in the lung epithelial cell line A549: transcriptional effect on the GSH rate-limiting enzyme gamma-glutamylcysteine synthetase. Am. J. Respir. Cell Mol. Biol. 17 (1997) 599-607
308. Pittet J.F., Griffiths M.J., Geiser T., Kaminski N., Dalton S.L., Huang X., Brown L.A., Gotwals P.J., Koteliansky V.E., Matthay M.A., and Sheppard D. TGF-beta is a critical mediator of acute lung injury. J. Clin. Invest. 107 (2001) 1537-1544
309. Jardine H., MacNee W., Donaldson K., and Rahman I. Molecular mechanism of transforming growth factor (TGF)-beta1-induced glutathione depletion in alveolar epithelial cells: involvement of AP-1/ARE and Fra-1. J. Biol. Chem. 277 (2002) 21158-21166
310. Franklin C.C., Rosenfeld-Franklin M.E., White C., Kavanagh T.J., and Fausto N. TGFbeta1-induced suppression of glutathione antioxidant defenses in hepatocytes: caspase-dependent post-translational and caspase-independent transcriptional regulatory mechanisms. FASEB J. 17 (2003) 1535-1537
311. Bakin A.V., Stourman N.V., Sekhar K.R., Rinehart C., Yan X., Meredith M.J., Arteaga C.L., and Freeman M.L. Smad3-ATF3 signaling mediates TGF-β suppression of genes encoding Phase II detoxifying proteins. Free Radic. Biol. Med. 38 (2005) 375-387
312. Liu R.-M., Liu Y., Forman H.J., Olman M., and Tarpey M.M. Glutathione regulates transforming growth factor-β-stimulated collagen production in fibroblasts. Am. J. Physiol. Lung Cell Mol. Physiol. 286 (2004) L121-128
313. Tiitto L.H., Peltoniemi M.J., Kaarteenaho-Wiik R.L., Soini Y.M., Paakko P.K., Sormunen R.T., and Kinnula V.L. Cell-specific regulation of gamma-glutamylcysteine synthetase in human interstitial lung diseases. Hum. Pathol. 35 (2004) 832-839
314. Wu G., Fang Y.Z., Yang S., Lupton J.R., and Turner N.D. Glutathione metabolism and its implications for health. J. Nutr. 134 (2004) 489-492
315. Baumgardner J.N., Shankar K., Hennings L., Albano E., Badger T.M., and Ronis M.J.J. N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J. Nutr. 138 (2008) 1872-1879
316. Yang Y.Y., Lee K.C., Huang Y.T., Wang Y.W., Hou M.C., Lee F.Y., Lin H.C., and Lee S.D. Effects of N-acetylcysteine administration in hepatic microcirculation of rats with biliary cirrhosis. J. Hepatol. 49 (2008) 25-33
317. Vendemiale G., Grattagliano I., Caruso M.L., Serviddio G., Valentini A.M., Pirrelli M., and Altomare E. Increased oxidative stress in dimethylnitrosamine-induced liver fibrosis in the rat: effect of N-acetylcysteine and interferon-α. Toxicol. Appl. Pharmacol. 175 (2001) 130-139
318. Pereira-Filho G., Ferreira C., Schwengber A., Marroni C., Zettler C., and Marroni N. Role of N-acetylcysteine on fibrosis and oxidative stress in cirrhotic rats. Arq. Gastroenterol. 45 (2008) 156-162
319. Shahzeidi S., Sarnstrand B., Jeffery P.K., McAnulty R.J., and Laurent G.J. Oral N-acetylcysteine reduces bleomycin-induced collagen deposition in the lungs of mice. Eur. Respir. J. 4 (1991) 845-852
320. Cortijo J., Cerda-Nicolas M., Serrano A., Bioque G., Estrela J.M., Santangelo F., Esteras A., Llombart-Bosch A., and Morcillo E.J. Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats. Eur. Respir. J. 17 (2001) 1228-1235
321. Mata M., Ruiz A., Cerda M., Martinez-Losa M., Cortijo J., Santangelo F., Serrano-Mollar A., Llombart-Bosch A., and Morcillo E.J. Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats. Eur. Respir. J. 22 (2003) 900-905
322. Hagiwara S.I., Ishii Y., and Kitamura S. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am. J. Respir. Crit. Care Med. 162 (2000) 225-231
323. Sime P.J., and O'Reilly K.M. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin. Immunol. 99 (2001) 308-319
324. Selman M., Thannickal V.J., Pardo A., Zisman D.A., Martinez F.J., and Lynch III J.P. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 64 (2004) 405-430
325. Hunninghake G.W. Antioxidant therapy for idiopathic pulmonary fibrosis. N. Engl. J. Med. 353 (2005) 2285-2287
326. King Jr. T.E. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am. J. Respir. Crit. Care Med. 172 (2005) 268-279
327. Ziesche R., Hofbauer E., Wittmann K., Petkov V., and Block L.H. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 341 (1999) 1264-1269
328. Raghu G., Brown K.K., Bradford W.Z., Starko K., Noble P.W., Schwartz D.A., and King Jr. T.E. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 350 (2004) 125-133
329. Prasse A., Muller K.M., Kurz C., Hamm H., and Virchow Jr. J.C. Does interferon-gamma improve pulmonary function in idiopathic pulmonary fibrosis?. Eur. Respir. J. 22 (2003) 906-911
330. Selman M. A dark side of interferon-gamma in the treatment of idiopathic pulmonary fibrosis?. Am. J. Respir. Crit. Care Med. 167 (2003) 945-946
331. Tomioka H., Kuwata Y., Imanaka K., Hashimoto K., Ohnishi H., Tada K., Sakamoto H., and Iwasaki H. A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis. Respirology 10 (2005) 449-455
332. Demedts M., Behr J., Buhl R., Costabel U., Dekhuijzen R., Jansen H.M., MacNee W., Thomeer M., Wallaert B., Laurent F., Nicholson A.G., Verbeken E.K., Verschakelen J., Flower C.D., Capron F., Petruzzelli S., De Vuyst P., van den Bosch J.M., Rodriguez-Becerra E., Corvasce G., Lankhorst I., Sardina M., and Montanari M. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 353 (2005) 2229-2242
333. Gao L., Broughman J.R., Iwamoto T., Tomich J.M., Venglarik C.J., and Forman H.J. Synthetic chloride channel restores glutathione secretion in cystic fibrosis airway epithelia. Am. J. Physiol. Lung Cell Mol. Physiol. 281 (2001) L24-30
334. Kogan I., Ramjeesingh M., Li C., Kidd J.F., Wang Y., Leslie E.M., Cole S.P., and Bear C.E. CFTR directly mediates nucleotide-regulated glutathione flux. EMBO J. 22 (2003) 1981-1989
335. Kariya C., Leitner H., Min E., van Heeckeren C., van Heeckeren A., and Day B.J. A role for CFTR in the elevation of glutathione levels in the lung by oral glutathione administration. Am. J. Physiol. Lung Cell Mol. Physiol. 292 (2007) L1590-L1597
336. Stafanger G., Garne S., Howitz P., Morkassel E., and Koch C. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. Eur. Respir. J. 1 (1988) 161-167
337. Griese M., Ramakers J., Krasselt A., Starosta V., Van Koningsbruggen S., Fischer R., Ratjen F., Mullinger B., Huber R.M., Maier K., Rietschel E., and Scheuch G. Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am. J. Respir. Crit. Care Med. 169 (2004) 822-828
338. Hartl D., Starosta V., Maier K., Beck-Speier I., Rebhan C., Becker B.F., Latzin P., Fischer R., Ratjen F., Huber R.M., Rietschel E., Krauss-Etschmann S., and Griese M. Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs. Free Radic. Biol. Med. 39 (2005) 463-472
339. Bishop C., Hudson V.M., Hilton S.C., and Wilde C. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest 127 (2005) 308-317